+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prostate Health Market by Disease Type, Therapy Type, Drug Treatment Type - Global Forecast 2025-2030- Product Image
Prostate Health Market by Disease Type, Therapy Type, Drug Treatment Type - Global Forecast 2025-2030- Product Image
Sale

Prostate Health Market by Disease Type, Therapy Type, Drug Treatment Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5639425
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Prostate Health Market grew from USD 52.13 billion in 2023 to USD 57.48 billion in 2024. It is expected to continue growing at a CAGR of 10.74%, reaching USD 106.49 billion by 2030.

The prostate health market pertains to the diagnosis, treatment, and maintenance of the prostate gland, which is a crucial aspect of male reproductive health. This market encompasses products and services including pharmaceuticals, dietary supplements, medical devices, and diagnostics specifically targeting conditions such as benign prostatic hyperplasia (BPH), prostate cancer, and prostatitis. The necessity for this market arises from the high incidence of prostate-related conditions among aging males, progressive advancements in medical technologies, and the increasing emphasis on men's health awareness programs. The applications span therapeutic interventions, preventive care strategies, and regular health screenings, with significant end-use adoption in hospitals, clinics, and homecare settings.

Key growth factors include the growing aging male population, escalating healthcare expenditures, and technological innovations in diagnostics and minimally invasive treatments. Moreover, lifestyle changes and increased adoption of early detection measures have spurred market growth. Potential opportunities lie in personalized medicine approaches that cater to genetic and lifestyle factors influencing prostate health, as well as increased awareness through telemedicine solutions catering to remote areas. To capitalize on these opportunities, market players should invest in strategic partnerships, innovative product development, and awareness campaigns to enhance market penetration.

Limitations and challenges include high costs associated with advanced treatment options, potential side effects from pharmaceutical interventions, and regulatory hurdles affecting market entry. Additionally, varying healthcare infrastructures across regions could impede consistent growth, with hesitancy and stigmas surrounding male health further restraining market expansion. For business growth, innovation areas such as AI-driven diagnostic tools, non-invasive treatments, and nutraceuticals offer promising prospects. Insight into the market nature suggests a competitive landscape with strong R&D activities and a focus on sustainability and cost-effectiveness. Companies should prioritize holistic approaches and adapt to demographic trends to capture the full market potential.

Understanding Market Dynamics in the Prostate Health Market

The Prostate Health Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising aging population and increasing prevalence rate of benign prostatic hyperplasia and prostate cancer
    • Growing government’s initiatives for advancement in technology in diagnosis
    • Innovation in hormone therapy drugs and developments genomics and proteomics
  • Market Restraints
    • Side-effects associated with BPH medications
  • Market Opportunities
    • Increasing researches leading to development of new drugs like Rucaparib and Olaparib
    • Development of novel modality of therapy for prostate cancer
  • Market Challenges
    • Low awareness regarding prostate health

Exploring Porter’s Five Forces for the Prostate Health Market

Porter’s Five Forces framework further strengthens the insights of the Prostate Health Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Prostate Health Market

External macro-environmental factors deeply influence the performance of the Prostate Health Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Prostate Health Market

The Prostate Health Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Prostate Health Market

The Prostate Health Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Prostate Health Market

The Prostate Health Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Prostate Health Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc., GlaxoSmithKline PLC, Ipsen Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Ltd..

Market Segmentation & Coverage

This research report categorizes the Prostate Health Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Disease Type
    • Benign Prostatic Hyperplasia
    • Prostate Cancer
    • Prostatitis
  • Therapy Type
    • AR-Directed Therapies
    • Cytotoxic Agents
    • Hormone ADT
    • Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
  • Drug Treatment Type
    • 5-Alpha Reductase Inhibitors
      • Dutasteride
      • Finasteride
    • Alpha Blockers
      • Alfuzosin
      • Doxazosin
      • Silodosin
      • Tamsulosin
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising aging population and increasing prevalence rate of benign prostatic hyperplasia and prostate cancer
5.1.1.2. Growing government’s initiatives for advancement in technology in diagnosis
5.1.1.3. Innovation in hormone therapy drugs and developments genomics and proteomics
5.1.2. Restraints
5.1.2.1. Side-effects associated with BPH medications
5.1.3. Opportunities
5.1.3.1. Increasing researches leading to development of new drugs like Rucaparib and Olaparib
5.1.3.2. Development of novel modality of therapy for prostate cancer
5.1.4. Challenges
5.1.4.1. Low awareness regarding prostate health
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Prostate Health Market, by Disease Type
6.1. Introduction
6.2. Benign Prostatic Hyperplasia
6.3. Prostate Cancer
6.4. Prostatitis
7. Prostate Health Market, by Therapy Type
7.1. Introduction
7.2. AR-Directed Therapies
7.3. Cytotoxic Agents
7.4. Hormone ADT
7.5. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
8. Prostate Health Market, by Drug Treatment Type
8.1. Introduction
8.2. 5-Alpha Reductase Inhibitors
8.2.1. Dutasteride
8.2.2. Finasteride
8.3. Alpha Blockers
8.3.1. Alfuzosin
8.3.2. Doxazosin
8.3.3. Silodosin
8.3.4. Tamsulosin
9. Americas Prostate Health Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Prostate Health Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Prostate Health Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. PROSTATE HEALTH MARKET RESEARCH PROCESS
FIGURE 2. PROSTATE HEALTH MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL PROSTATE HEALTH MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. PROSTATE HEALTH MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. PROSTATE HEALTH MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. PROSTATE HEALTH MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL PROSTATE HEALTH MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. PROSTATE HEALTH MARKET DYNAMICS
TABLE 7. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AR-DIRECTED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HORMONE ADT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PROSTATE HEALTH MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PROSTATE HEALTH MARKET SIZE, BY SILODOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 43. CANADA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 44. CANADA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 45. CANADA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 46. CANADA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 47. CANADA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 48. MEXICO PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 49. MEXICO PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 50. MEXICO PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 51. MEXICO PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 52. MEXICO PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 70. CHINA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 71. CHINA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 72. CHINA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. CHINA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 74. CHINA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 75. INDIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 76. INDIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 77. INDIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. INDIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. INDIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 85. JAPAN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 86. JAPAN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 87. JAPAN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. JAPAN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 89. JAPAN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 115. THAILAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 116. THAILAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 117. THAILAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 118. THAILAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 119. THAILAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 131. DENMARK PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 132. DENMARK PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 133. DENMARK PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. DENMARK PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 135. DENMARK PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 136. EGYPT PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 137. EGYPT PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 138. EGYPT PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. EGYPT PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. EGYPT PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 141. FINLAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 142. FINLAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 143. FINLAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 144. FINLAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. FINLAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 146. FRANCE PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 147. FRANCE PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 148. FRANCE PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. FRANCE PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 151. GERMANY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 152. GERMANY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 153. GERMANY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 154. GERMANY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 155. GERMANY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 161. ITALY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 162. ITALY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 163. ITALY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. ITALY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 165. ITALY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 176. NORWAY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 177. NORWAY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 178. NORWAY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. NORWAY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. NORWAY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 181. POLAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 182. POLAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 183. POLAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. POLAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 185. POLAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 186. QATAR PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 187. QATAR PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 188. QATAR PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. QATAR PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. QATAR PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 206. SPAIN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 207. SPAIN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 208. SPAIN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. SPAIN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. SPAIN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 221. TURKEY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 222. TURKEY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 223. TURKEY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. TURKEY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 236. PROSTATE HEALTH MARKET SHARE, BY KEY PLAYER, 2023
TABLE 237. PROSTATE HEALTH MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Prostate Health Market, which are profiled in this report, include:
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Elekta AB
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals Inc.
  • GlaxoSmithKline PLC
  • Ipsen Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 57.48 Billion
Forecasted Market Value ( USD ) by 2030 $ 106.49 Billion
Compound Annual Growth Rate10.7%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Benign Prostatic Hypertrophy Drugs Market by Product, Sales Channel - Global Forecast 2025-2030 - Product Image

Benign Prostatic Hypertrophy Drugs Market by Product, Sales Channel - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report - Product Image

Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class, Therapy, End User - Global Forecast 2025-2030 - Product Image

Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class, Therapy, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032 - Product Image

Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032

  • Report
  • 148 Pages
  • Global
From
Prostate Cancer - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Prostate Cancer - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From

About the Prostate Health Market

The Prostate Health market is a subset of the pharmaceutical industry focused on the development and sale of drugs to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it are typically hormone therapy, chemotherapy, and radiation therapy. These drugs are used to reduce the size of the tumor, slow its growth, and reduce the risk of metastasis. In addition, some drugs are used to reduce the side effects of prostate cancer treatments, such as fatigue, nausea, and sexual dysfunction. The Prostate Health market is highly competitive, with many companies offering a variety of drugs to treat prostate cancer. Some of the major players in the market include AstraZeneca, Pfizer, Merck, and Johnson & Johnson. Other companies in the market include AbbVie, Bristol-Myers Squibb, and Sanofi. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.